HIV Prevention Review Meeting 2022

In 2020, 1.5 million new HIV cases were reported worldwide. To end the HIV epidemic, effective prevention strategies are critical. The efficacy and effectiveness of the first approved PrEP regimens at the individual and population levels have fueled further research, and we are currently in the midst of a new exciting chapter. The diversity in new drugs and their formulations, including long-acting injectables, implants, and vaginal rings highlights a sustained educational need. Real-world data suggest different challenges in PrEP implementation, such as the perception of risk, compromised adherence, costs, availability, and structural barriers. Implementation challenges reflect regional differences in healthcare settings indicating a need for tailored educational programs to discuss best practices and better align guidelines and policies inclusive to all at-risk groups.

The HIV Prevention Series is designed to promote understanding among physicians, nurses, policymakers, and community advocates on antiretroviral drugs for prevention, novel formulations, and devices. It also includes implementation strategies and individual and community-based behavioral aspects of prevention as well as insights into the vaccine landscape and prospects of monoclonal antibodies for HIV prevention.

The HIV Prevention Review Meeting 2022 provided an overview of scientific advances, the importance of these findings, and their implications for the implementation of prevention programs.

This will be followed by the Asia-Pacific regional program, that will focus on regional guidelines, barriers to PrEP access, and strategies to overcome those. 

General Information 

We trust that the following information (in alphabetical order) will assist you in organising your participation in the HIV Prevention Review Program 2022.

The HIV Prevention Review Program 2022 is endorsed by the following societies and organizations. Their support and collaboration are key to the success of this program!

If you would like your Organization to endorse this meeting, please contact Rikke at Rikke.Rode@amededu.com.

The HIV Prevention Review Meeting 2022, Utrecht (Livestream), Netherlands, 30/03/2022 - 31/03/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 4 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Please note that CME accreditation is only provided for delegates that attended the event livestream.

An online survey was sent out to all attendees at the end of the meeting. After completing the survey, a CME certificate will be sent to your registration email. If you have any questions regarding claiming CME credits, please contact eva.vamvounaki@amededu.com. Please note that CME accreditation is only provided for delegates that attended the event Livestream.

See the invitation from our faculty members to join the HIV Prevention Review Meeting 2022 below.

François Venter, MD, FCP, PhD - Ezintsha, University of the Witwatersrand, South Africa

Maureen Luba - AIDS Vaccine Advocacy Coalition, Malawi

• 1st Edition, HIV Prevention Review Meeting, 2021, Virtual

HIV Vaccine Landscape - Larry Corey, MD

HIV Prevention Review Meeting 2021